Future Development Plans Sample Clauses
Future Development Plans. Batch Processing (▇▇▇▇▇▇) gave an overview of the current status of, and plans for further developing, batch processing capabilities within ESAP. Refer to §§2.3.7 & 2.4 of this document for an overview of these plans. A key aim of this talk was to solicit guidance from the community about which batch systems they regard as a priority, as well as developer effort to help integrate ESAP with their own systems. The WP5 leadership adopts the position that selection of a batch system or systems should be largely community driven: rather than WP5 choosing a standardized system, WP5 will work with the community to enable whatever batch systems they require (within the limits of available resources). The primary advocates of ESAP interfaces with batch computing come from CTA, who require interfaces with DIRAC. We agreed that development would prioritize this work; members of the community were encouraged to work with WP5 developers to push this effort forward. Managed Database (▇▇▇▇▇▇▇) discussed the Managed Database service being proposed for ESAP (§2.3.9), including an impressive live demo. The discussion focused around technical aspects of the system: the tech‐ nologies used, and how they could be integrated with the rest of the ESAP system. The suggestion of the Managed Database service being used as the basis for potential improvements to the shopping basket (§2.3.3) was discussed. This could unlock a range of new possibilities. However, the Managed Database is currently an immature prototype, and the work package is cognizant of its commitments to make robust deliveries of promised functionality on time. The current plan is therefore to continue development of the existing shopping basket system, while working on the Managed Database service in parallel and remaining alert to opportunities for future enhancements. Interested members of the community were encouraged to connect directly with the WP5 developers to provide additional use cases and guide the development effort.
Future Development Plans. Alios and Vertex plan to initiate clinical development of each compound in the fourth quarter of 2011, which is expected to include studies of the compounds in healthy volunteers followed by short-duration safety and viral kinetic studies in people with hepatitis C. The goal of the first clinical studies of these compounds is to generate data to enable the initiation of Phase 2 studies as early as the end of 2012. These Phase 2 studies are expected to evaluate multiple combination regimens of ALS-2200, ALS-2158, INCIVEK and VX-222. The combination studies would be designed to generate sustained viral response (SVR or viral cure) data. Additional details on the clinical development program for ALS-2200 and ALS-2158 will be provided later in 2011 upon initiation of the first clinical study. As part of the agreement, Alios will receive a $60 million up-front payment from Vertex for the worldwide rights to ALS-2200 and ALS-2158. Vertex is responsible for development costs related to ALS-2200 and ALS-2158 and will also provide research funding to Alios. In addition, Alios would be eligible to receive research and development milestone payments up to $715 million if both compounds are approved. Vertex expects to pay approximately $35 million in development milestones in 2011. Alios is also eligible to receive up to $750 million in sales milestones on sales of all approved medicines under the collaboration. The agreement also includes tiered royalties on product sales. Important Information About INCIVEKTM (telaprevir) tablets INCIVEKTM (telaprevir) is a prescription medicine used with the medicines peginterferon alfa and ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1 infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment. It is not known if INCIVEK is safe and effective in children under 18 years of age. INCIVEK should always be taken in combination with peginterferon alfa and ribavirin. Ribavirin may cause birth defects or death of an unborn baby. Therefore, you should not take INCIVEK combination treatment if you are pregnant or may become pregnant, or if you are a man with a sexual partner who is pregnant. INCIVEK and other medicines can affect each other and can also cause side effects that can be serious or life threatening. There are certain medicines you cannot take with INCIVEK combination treatment. Tell your healthcare provider about all the medicines you take, inc...